CeaproTSXV: CZO

Ceapro announces new Controller

· Issued by Ceapro via CNW
EDMONTON, April 21 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced that
Mr. Shawn McMillan, CA has joined the Company as Controller. Mr. McMillan
assumes responsibility for the accounting and financial functions of Ceapro
and will be instrumental in assisting with future financings.
"We are pleased to welcome Shawn to the Ceapro team at an important time
in the Company's evolution," said Dr. Mark Redmond, President and CEO. "Our
business is focused on growth and as we roll out new products such as
CeaProve(TM), our diabetes management technology, Shawn will play a leading
role in our financial and strategic planning activities."
Mr. McMillan earned his Bachelor of Commerce degree in Accounting from
the University of Alberta in 2002. He gained experience in public company
reporting and accounting with Deloitte & Touche LLP in Edmonton, Alberta and
obtained his Chartered Accountant designation in 2005.

2004 Financial Results and Annual and Special Meeting

Ceapro will release its 2004 financial results on or before April 29,
2005. The Company's annual report, containing Management's Discussion and
Analysis and Audited Financial Statements, will be mailed to shareholders on
or about May 2, 2005. Ceapro's annual and special meeting of shareholders will
be held on Wednesday, June 1, 2005, at Lister Centre, University of Alberta,
at 3:00 p.m. MDT

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than $25
million. Ceapro's shares trade on the TSX Venture Exchange under the symbol
CZO. To learn more about Ceapro, log on to our website at www.ceapro.com.
Shares Outstanding: 36,355,950, Recent Close: $0.30.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.
%SEDAR: 00010110E

Ceapro on 6ix

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases